USP Drug Classification

[ Brite menu | Download htext | Download json ]
    

1st Level  2nd Level  3rd Level  4th Level 

 Analgesics
 
 Anesthetics
 
 Anti-Addiction/Substance Abuse Treatment Agents
 
 Antibacterials
 
 Anticonvulsants
 
 Antidementia Agents
 
 Antidepressants
 
 Antiemetics
 
 Antifungals
 
 Antigout Agents
 
 Anti-inflammatory Agents
 
 Antimigraine Agents
 
 Antimyasthenic Agents
 
 Antimycobacterials
 
 Antineoplastics
 
 Antiparasitics
 
 Antiparkinson Agents
 
 Antipsychotics
 
 Antispasticity Agents
 
 Antivirals
 
 Anxiolytics
 
 Bipolar Agents
 
 Blood Glucose Regulators
 
 Blood Products/Modifiers/Volume Expanders
 
 Cardiovascular Agents
 
 Central Nervous System Agents
   Attention Deficit Hyperactivity Disorder Agents, Amphetamines
   Attention Deficit Hyperactivity Disorder Agents, Non- amphetamines
   Fibromyalgia Agents
   Multiple Sclerosis Agents
     Interferon beta-1a
     Interferon beta-1b
     Dalfampridine
     Teriflunomide
     Fingolimod [DG:DG00741]
     Dimethyl fumarate
     Glatiramer
     Mitoxantrone [DG:DG00701]
     Peginterferon Beta 1A
     Natalizumab
       D06886  Natalizumab (INN)
     Daclizumab
   Central Nervous System, Other
 
 Dental and Oral Agents
 
 Dermatological Agents
 
 Electrolytes/Minerals/Metals/Vitamins
 
 Gastrointestinal Agents
 
 Genetic or Enzyme Disorder: Replacement, Modifiers, Treatment
 
 Genitourinary Agents
 
 Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
 
 Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)
 
 Hormonal Agents, Stimulant/Replacement/Modifying (Prostaglandins)
 
 Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
 
 Hormonal Agents, Stimulant/Replacement/Modifying (Thyroid)
 
 Hormonal Agents, Suppressant (Adrenal)
 
 Hormonal Agents, Suppressant (Pituitary)
 
 Hormonal Agents, Suppressant (Thyroid)
 
 Immunological Agents
   Angioedema Agents
   Immune Suppressants
   Immunizing Agents, Passive
   Immunomodulators
     Belimumab
     Interferon gamma-1b, Recombinant
     Canakinumab
     Rilonacept
     Siltuximab
     Tocilizumab
     Auranofin
     Apremilast
     Leflunomide
     Natalizumab
       D06886  Natalizumab (INN)
     Omalizumab
     Vedolizumab
   Vaccines
 
 Inflammatory Bowel Disease Agents
 
 Metabolic Bone Disease Agents
 
 Ophthalmic Agents
 
 Otic Agents
 
 Respiratory Tract/Pulmonary Agents
 
 Skeletal Muscle Relaxants
 
 Sleep Disorder Agents

[ DRUG | BRITE | KEGG2 | KEGG ]
Last updated: July 12, 2017
According to the USP Medicare Model Guidelines v7.0

» Japanese version